Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + darunavir/cobicistat simplification versus optimized treatment in suppressed multidrug-resistant HIV-1
2017-004750-42Phase 4Active
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dolutegravir, darunavir and cobicistat in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Virologic suppression at Week 48. Started Jun 2018; status: active.
02
Drugs
dolutegravirdarunavircobicistat
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-004750-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004750-42.